Graybug Vision, Inc. was a clinical-stage ophthalmology company developing sustained-release therapies for retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Its lead program, GB-102, was designed to reduce treatment burden through long-acting drug delivery before the company merged with CalciMedica in 2023.

 

IPO in September 2020 (NASDAQ: GRAY).

 

VISIT WEBSITE